GlobeNewsWire
17 Jul 2026, 14:42 UTC · 14w ago
Impact · against what's priced in
Compass Therapeutics has a positive catalyst upcoming with the oral presentation of COMPANION-002 data at the ESMO Congress on October 24, 2026. The acceptance of an oral Proffered Paper suggests the data is clinically significant, providing a near-term valuation driver.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Compass Therapeutics' Phase 2/3 COMPANION-002 trial results for tovecimig in advanced biliary tract cancer have been accepted for an oral Proffered Paper presentation at the ESMO Congress on October 24, 2026.
More positive than 79% of claims this week
The company expects to receive feedback from the FDA during the current quarter regarding the COMPANION-002 Phase 2/3 data.
Continue reading
5 related stories
The acceptance of the COMPANION-002 biliary tract cancer trial results for an oral Proffered Paper presentation at ESMO typically indicates high-quality data, creating a tangible catalyst for October 24.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 66% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company's clinical trial data for tovecimig was accepted for an oral presentation at a major medical congress (ESMO).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Globe News Wire
4h ago
−63.8%
Price is moving against the score
$0.7610 vs $2.10 close before publication (Jul 16) · not market-adjusted
CMPX chart →
